Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
1-15 of 4259 results
Orano Med, RadioMedix recruit first patients in AlphaMedix phase 1 clinical trial
Orano Med and RadioMedix have recruited first three patients in the AlphaMedix phase 1 clinical trial.
Contract Research & Services > Clinical Trials > News
Sterna reports positive results in severe ulcerative colitis drug trial
By PBR Staff Writer
sterna biological has reported positive results from the SECURE study, a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its GATA-3 specific DNAzyme formulation SB012.
Contract Research & Services > Clinical Trials > News
BerGenBio completes recruitment into first stage of phase II breast cancer trial
BerGenBio has completed enrolment of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib (BGB324) in combination with the Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a potential new treatment regimen for advanced breast cancer.
Contract Research & Services > Clinical Trials > News
Lilly’s Taltz yields positive results in phase 3 genital psoriasis trial
By PBR Staff Writer
Eli Lilly and Company reported that Taltz (ixekizumab) in a phase 3b trial has helped patients with moderate-to-severe genital psoriasis in significantly reducing the impact of their condition on sexual activity.
Contract Research & Services > Clinical Trials > News
Novartis' Cosentyx improves skin clearance in scalp psoriasis study
By PBR Staff Writer
Novartis has announced that its Cosentyx (secukinumab) improved skin clearance in patients with scalp psoriasis in the phase III Scalp study.
Contract Research & Services > Clinical Trials > News
Seikagaku begins phase 3 US trial for SI-6603 for lumbar disc herniation
Seikagaku has started a phase 3 clinical trial in the US for SI-6603 (Condoliase), indicated for the treatment of radicular leg pain (sciatica) due to a lumbar disc herniation.
Contract Research & Services > Clinical Trials > News
Cancer Research UK announces £45m investment in clinical trials
By PBR Staff Writer
Cancer Research UK is set to invest £45m in its network of clinical trials units (CTUs) across the country, enabling clinicians to develop treatments and tests for cancer patients.
Contract Research & Services > Clinical Trials > News
Lilly’s radiographic axial spondyloarthritis treatment Taltz succeeds in phase 3 study
Eli Lilly announced that Taltz (ixekizumab) has met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (axSpA).
Contract Research & Services > Clinical Trials > News
Diurnal Group completes patient enrolment in Chronocort’s trial for congenital adrenal hyperplasia
Diurnal Group has completed patient enrolment in its European pivotal Phase III clinical trial of Chronocort (modified release hydrocortisone) for the treatment of congenital adrenal hyperplasia (CAH) in adults.
Contract Research & Services > Clinical Trials > News
Apalutamide delays spread of several prostate cancers in phase 3 trial
By PBR Staff Writer
A group of investigators have demonstrated in a phase 3 clinical trial that apalutamide, an inhibitor of androgen receptor, delays spread of certain prostate cancers that had become resistant to standard androgen-deprivation therapy.
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Brilinta shows benefits for heart attack patients in phase III trial
AstraZeneca’s Brilinta significantly reduced cardiovascular (CV) events and coronary death beyond one year in heart attack survivors with multi-vessel disease in a Phase III trial.
Contract Research & Services > Clinical Trials > News
Roche’s Tecentriq/Avastin combo succeeds in phase 3 kidney cancer trial
By PBR Staff Writer
Roche said that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26% in certain people with advanced kidney cancer in a Phase III study.
Contract Research & Services > Clinical Trials > News
Shield’s Feraccru fails to demonstrate efficacy to treat IDA in CKD patients
By PBR Staff Writer
Shield Therapeutics’ Feraccru (ferric maltol) oral ferric iron therapy has failed to meet the primary efficacy endpoint in the AEGIS-CKD phase III study for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).
Contract Research & Services > Clinical Trials > News
BMS’ Opdivo-Yervoy combo succeeds in phase 3 NSCLC trial
By PBR Staff Writer
Bristol-Myers Squibb (BMS) said that the combination of its immuno-oncology drugs Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated superior progression-free survival (PFS) in first-line non-small cell lung cancer (NSCLC) patients with high tumor mutation burden (TMB) in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
PharmAbcine, Merck to assess TTAC-0001 in combination with Keytruda in recurrent rlioblastoma and breast cancer
PharmAbcine has signed a collaborative agreement with Merck (MSD) to evaluate its anti-VEGFR2 mAb, TTAC-0001, in combination with MSD’s anti-PD-1 (programmed death receptor-1) therapy, Keytruda (pembrolizumab), in patients with recurrent glioblastoma multiforme (rGBM) and metastatic triple-negative breast cancer (TNBC).
Contract Research & Services > Clinical Trials > News
1-15 of 4259 results